Real‐World Associations of Renin–Angiotensin–Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New‐Onset Chronic Kidney Disease or Heart Failure in the United Kingdom

BACKGROUND: Dosing of renin–angiotensin–aldosterone system inhibitors (RAASi) may be modified to manage associated hyperkalemia risk; however, this approach could adversely affect cardiorenal outcomes. This study investigated real‐world associations of RAASi dose, hyperkalemia, and adverse clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Linde, Cecilia, Bakhai, Ameet, Furuland, Hans, Evans, Marc, McEwan, Phil, Ayoubkhani, Daniel, Qin, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915283/
https://www.ncbi.nlm.nih.gov/pubmed/31711387
http://dx.doi.org/10.1161/JAHA.119.012655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915283/
https://www.ncbi.nlm.nih.gov/pubmed/31711387
http://dx.doi.org/10.1161/JAHA.119.012655

Ejemplares similares